4th ESO-ESMO Latin-American Masterclass in Clinical Oncology

Chairs: A. Cervantes, ES - N. Pavlidis, GR - R.A. Stahel, CH
Scientific Co-ordinators: M. Aapro, CH - F. Cardoso, PT


The Masterclass is the most structured ESO educational activity whose format has been established and presented in Europe for over a decade. The success of the teaching method has been confirmed by the events held also in other parts of the world as well as by the three editions held in Latin America. It is with pleasure and gratefulness for the consideration of the local community, that ESO announces the fourth edition to be held in the region in 2018.
The Masterclass offers plenary lectures discussing current issues and controversies as well as critically reviewing significant therapeutic developments. State-of-the-art data recognized by ESMO and other evidence-based guidelines will be cited.
Participants will deliver case presentations within tumour boards and small groups and discuss them with the chairs and the faculty. As for all Masterclasses, the number of participants will be limited and admission will be by competitive application only. Admitted participants will be granted free registration and half-board accommodation for the duration of the Masterclass.

LEARNING OBJECTIVES
• Improve medical oncologists’ skills
• Practicing case discussion
• Deep focus on breast, gastro-intestinal, genitourinary, gynaecological, head and neck and lung cancers
• Compact update on further topics of interest

MAIN TOPICS
• Breast cancer
• Gastro-intestinal cancers
• Genito-urinary cancers
• Gynaecological cancers
• Head and neck cancer
• Lung cancer

The Latin-American Masterclass in Clinical Oncology is an ESO-ESMO joint event
Under the auspices of

FACULTY 
M.S. Aapro, Clinique de Genolier, Genolier, CH
O. Arrieta, Instituto Nacional de Cancerologia (INcan), Mexico City, MX
M.T. Bourlon, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MX
M. Campbell, The University of Texas MD Anderson Cancer Center, Houston, US
F. Calvo, Clinica Universidad de Navarra, Madrid, ES
F. Cardoso, Champalimaud Cancer Center, Lisbon, PT
P. Casali, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
F. Cavalli, Oncology Institute of Southern Switzerland, Bellinzona, CH
A. Cervantes, University Clinical Hospital, Valencia, ES
G. Curigliano, European Institute of Oncology, Milan, IT
M. Del Pilar Estevez Diz, Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR
C.Z. Deneken, FUCAM, Mexico City, MX
E. Efstathiou, University of Texas MD Anderson Cancer Center, Houston, US
S.X. Franco, Clinical del Country, Bogota, CO
J.F. Gallegos Hernández, Hospital de Oncologia, Centro Médico Nacional Siglo XXI, Mexico City, MX
F. Geara, The American University of Beirut Medical Center, Beirut, LB
M. Gomez Cuadra, Angeles del Carmen, Guadalajara, MX
F. Knaul, University of Miami, Miami, US
E. Lazcano, El Instituto Nacional de Salud Pública, Cuernavaca, MX
S. Litière, European Organisation for Research and Treatment of Cancer EORTC, Brussels, BE
A. Mohar Betancourt, National Cancer Institute, Mexico City, MX
N. Pavlidis, University Hospital, Ioannina, GR
F.A. Peccatori, European School of Oncology and European Institute of Oncology, Milan, IT
F. Penault-Llorca, Centre Jean Perrin, Clermont-Ferrand, FR
S. Rivera Rivera, Centro Médico Nacional Siglo XXI and Sociedad Mexicana de Oncología, Mexico City, MX
E. Ruiz-Garcia, Instuto Nacional de Cancerologia, Mexico City, MX
J. Ruiz-Morales, Hospital Medica Sur, Mexico City, MX
V. Sacchini, European Institute of Oncology, Milan, IT
R.A. Stahel, University Hospital, Zurich, CH
R.M. Terra, University of São Paulo Medical School, São Paulo, BR
E. Van Cutsem, University Hospital Gasthuisberg, Leuven, BE
J.B. Vermorken, University Hospital Antwerp, Edegem, BE
G. Werutsky, Latin American Cooperative Oncology Group, Porto Alegre, BR

ORGANISING SECRETARIAT
European School of Oncology
Piazza Indipendeza 2, 6500 Bellinzona, Switzerland

Luis Carvalho, Ph: +41 91 820 09 58, E-mail: lcarvalho@eso.net
Alice Ciocchini, Ph +39 02 85464529, E-mail: aciocchini@eso.net

LANGUAGE
The Masterclass will be held in English and translation will not be provided.

CME AND ESMO MORA ACCREDITATION AND CERTIFICATES
Participants will be entitled to receive a certificate of attendance at the close of the Masterclass by completing the online evaluation questionnaire.
The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value. The event is designated for a maximum of 33 European CME credits (ECMEC). Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.
Furthermore, the conference has been accredited with 25 ESMO-MORA category 1 points.

INSURANCE AND SAFETY INFORMATION
The organisers bear no responsibility for untoward events in relation to the participation in the event. Participants and faculty members are advised to take their own personal and travel insurance coverage, take appropriate security measures and exercise caution in public places.

ESO CLINICAL TRAINING CENTRES FELLOWSHIP PROGRAMME
The ESO Clinical Training Centres Fellowship programme gives doctors who have specialized within the last 5 years the opportunity to request a training period of 3 or 6 months at one of the CTC Centres in Europe.
In Latin America only those who have taken part in the ESO-ESMO Latin-American Masterclass in Clinical Oncology and who meet the requirements can apply!
For further details please visit http://www.eso.net/varie/clinical-training-centres.html

SPONSORED LECTURES

Friday 20 April

19:30-20:00
Sponsored lecture 1: Bristol-Myers Squibb 

Today´s Role of Immuno-Oncology: From Statistical Significance to Clinical Benefit
S. Ponce, Hospital Universitario 12 de Octubre, Madrid, Spain

Saturday 21 April

19:00-19:30
Sponsored lecture 2: Roche

New Treatment Options for Patients with Lung Cancer
J.A. Alatorre Alexander, National Institute of Respiratory Diseases, Mexico City, Mexico

ACKNOWLEDGEMENTS
The Latin-American Masterclass in Clinical Oncology is funded by ESO and ESMO support with and unrestricted educational grants provided by BMS (Platinum sponsor), Roche (Platinum sponsor), Lilly (Gold sponsor) and Novartis (Gold sponsor) to whom ESO wishes to express its gratitude.

 18 April

 19 April

 20 April

 21 April

 22 April